Publications

Journal Article
Review
Ppublish 26 citations
Electronic publication date
March 17, 2007

View on Pubmed.gov 17315604 | View on doi.org 10.2147/vhrm.20...

Optimal lipid modification: the rationale for combination therapy.

Search for publications in this journal Vasc Health Risk Manag - 1(4):317-31

Abstract

BACKGROUND

An emphasis on more aggressive lipid-lowering, particularly of low-density lipoprotein cholesterol, to improve patient outcomes has led to an increased use of combination lipid-lowering drugs. This strategy, while potentially beneficial, has triggered concerns regarding fears of adverse effects, harmful drug interactions, and patient nonadherence.

OBJECTIVE

To present key data regarding combination lipid-altering therapy including use, rationale, major trials, benefits, potential adverse effects, compliance issues, and limitations.

METHOD

Literature was obtained from MEDLINE (1966 - June 2005) and references from selected articles.

RESULTS

A substantial body of evidence from epidemiological data and clinical trials indicates that aggressive lipid modification, especially low-density lipoprotein reduction, is associated with reduced cardiovascular events. Numerous studies utilizing various combinations of cholesterol-lowering agents including statin/fibrate, statin/niacin, statin/bile acid resin, and statin/ezetimibe have demonstrated significant changes in the lipid profile with acceptable safety. Long-term trials of combination therapy evaluating clinical outcomes or surrogate markers of cardiovascular disease, while limited, are promising.

CONCLUSION

Combining lipid-altering agents results in additional improvements in lipoproteins and has the potential to further reduce cardiovascular events beyond that of monotherapy.

References

Am J Cardiol. 2002 Mar 15;89(6):672-8

JAMA. 1984 Jan 20;251(3):351-64

Int J Cardiol. 2000 Jun 30;74 Suppl 1:S23-8

Clin Ther. 2003 Mar;25(3):904-18

Cited by 26 citations (total)

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

The effects of extended release niacin on lipoprotein sub-particle concentrations in HIV-infected patients.

Electronic publication date May 3, 2014

Search for publications in this journal Hawaii J Med Public Health

Chunrong Lin [...] Dominic Chow et al.

With the advent of highly active antiretroviral therapy (HAART), Cardiovascular Disease (CVD) has emerged as the leading cause of death...

Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial.

Electronic publication date January 23, 2018

Search for publications in this journal Br J Clin Pharmacol

Joana R Batuca [...] José Delgado Alves et al.

AIMS

Extended-release niacin (ERN) is the most effective agent for increasing high-density lipoprotein-cholesterol (HDL-C). Having previously identified anti-HDL antibodies, we investigated...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances